TriangleNCT02739594 · OUTCOME
Number of Zoledronate Dose Reductions for Each Participant
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- MEAN
- Unit
- dose reductions
- Interval / dispersion
- Standard Deviation
- Time frame
- From Baseline to end of study (up to Week 96)
What was measured
The number of zoledronate dose reductions was averaged across all participants, including those participants who did not have any dose reductions during the study.
Analysis population: ITT Population; only the Zoledronate arm was included.
Groups in this outcome
Zoledronate
Participants with multiple myeloma received zoledronate via 15-minute IV infusion as 4 mg every 4 weeks for up to 92 weeks. As a result of slow recruitment, the treatment duration was shortened to 40 weeks for participants who had not yet received 48 weeks of treatment. All participants returned for an additional follow-up observation 4 weeks after the end of treatment.
| Group | Source count |
|---|---|
| Zoledronate | 40 |
Reported measurements
Source class 1
| Group | Value | Spread | Lower | Upper | Comment |
|---|---|---|---|---|---|
| Zoledronate | 0.8 | 1.4 | Not reported | Not reported | Not reported |
Complete source fields
- classes
- categories
- measurements
- group Id
- OG000
- spread
- 1.4
- value
- 0.8
- denoms
- counts
- group Id
- OG000
- value
- 40
- units
- Participants
- description
- The number of zoledronate dose reductions was averaged across all participants, including those participants who did not have any dose reductions during the study.
- dispersion Type
- Standard Deviation
- groups
- description
- Participants with multiple myeloma received zoledronate via 15-minute IV infusion as 4 mg every 4 weeks for up to 92 weeks. As a result of slow recruitment, the treatment duration was shortened to 40 weeks for participants who had not yet received 48 weeks of treatment. All participants returned for an additional follow-up observation 4 weeks after the end of treatment.
- id
- OG000
- title
- Zoledronate
- param Type
- MEAN
- population Description
- ITT Population; only the Zoledronate arm was included.
- reporting Status
- POSTED
- time Frame
- From Baseline to end of study (up to Week 96)
- title
- Number of Zoledronate Dose Reductions for Each Participant
- type
- SECONDARY
- unit Of Measure
- dose reductions
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice